

Monday, September 22, 2008

Optional Introductory Program for delegates new to the field. \$50 Fee Required.	
7:00 - 5:00pm	<b>Registration</b> Crystal Ballroom Foyer
8:00 - 9:00am	<b>Breakfast</b> Crystal Ballroom Foyer
9:00 - 9:05am	<b>Welcome</b> Crystal Ballroom Elizabeth J Read, MD Director, Cell and Tissue Therapies, Blood Systems Research Institute, Adjunct Professor of Laboratory Medicine, University of California, San Francisco
9:05 - 10:30am	<b>Introduction to the Regulation of Cellular Therapies</b> Crystal Ballroom <b>Chair: Lynn O'Donnell, PhD</b> Director, Cell Therapy Laboratory, James Cancer Hospital & Research Institute, Ohio State University Mercy Quagraine, PhD OCTGT, CBER, FDA
10:30 - 11:30am	<b>Introduction to IND Preparation</b> Crystal Ballroom <b>IND Overview:</b> <b>Darin Weber, PhD</b> Senior Consultant, Biologics Consulting Group, Inc <b>CMC Section:</b> <b>Janice Davis-Sproul, MAS</b> Manager, Cell Therapy & Development Laboratory, Johns Hopkins Medicine

Monday, September 22, 2008 (continued)

Regular Program	
11:50 - 12:50pm	<b>Corporate Sponsored Lunch Session</b> <b>Cellgenix, AFC, Terumo</b> Crystal Ballroom Three talks aimed at describing current developments in sterile closed system cell processing, validation procedures, and related clinical experience. Lunch available in the Crystal Ballroom Foyer
1:00 - 1:10pm	<b>Welcome</b> Crystal Ballroom Elizabeth J Read, MD Director, Cell and Tissue Therapies, Blood Systems Research Institute, Adjunct Professor of Laboratory Medicine, University of California, San Francisco

Monday, September 22, 2008 (continued)

1:10 – 2:40pm	<p><b>FDA Update &amp; Overviews</b> <i>Crystal Ballroom</i></p> <p><b>CBER/OCTGT Update</b> Celia Witten, MD, PhD Director, OCTGT, CBER, FDA</p> <p><b>Challenges of Product Development</b> Darin Weber, PhD Senior Consultant, Biologics Consulting Group</p> <p><b>Approaches to Risk Assessment for Cellular Therapies</b> Brian Flynn Quality Manager, Genzyme Biosurgery</p>
2:40 – 3:30pm	<p><b>Qualification of Ancillary Reagents I</b> <i>Crystal Ballroom</i></p> <p><b>Chair: Bruce Levine, PhD</b> Director, Clinical Cell &amp; Vaccine Production Facility, University of Pennsylvania</p> <p><b>FDA Perspective</b> Steven Oh, PhD OCTGT, CBER, FDA</p> <p><b>Standards Setting for Ancillary Materials: USP Perspective</b> Fouad Atouf PhD Scientist, Biologics and Biotechnology, U.S. Pharmacopeia</p> <p><b>Standards Setting for Ancillary Materials: Industry Perspective</b> Gary du Moulin, PhD, MPH, RAC Senior Director, Quality Compliance Genzyme Biosurgery</p>
3:30 – 4:00pm	<p><b>Break &amp; Exhibits</b> <i>Crystal Ballroom Foyer</i></p>
4:00 – 5:00pm	<p><b>Qualification of Ancillary Reagents II</b> <i>Crystal Ballroom</i></p> <p><b>Panel Presentations &amp; Discussion:</b> Bruce Levine, PhD // Fouad Atouf, PhD // Gary du Moulin, PhD, MPH, RAC // Julia Goldstein, MD Senior Regulatory Affairs Officer, Office of Regulatory Affairs, NIAID, NIH</p>
5:00 – 6:10pm	<p><b>Challenges of International Studies from the Regulatory and Business Perspectives</b> <i>Crystal Ballroom</i></p> <p><b>Chair: Lee Buckler, BEd, LLB</b> Business Development, Progenitor Cell Therapy, LLC</p> <p><b>Panel Presentations &amp; Discussion:</b> Christopher Bravery, PhD Director of Regulatory Affairs (UK), ERA Consulting Elmar Burchardt, MD, PhD Vice President Medical Affairs, Aastrom Biosciences, Inc Kelly Ganjei Toucan Capital Corp.</p>
6:30 – 7:30pm	<p><b>Welcome Reception</b> <i>Crystal Ballroom Foyer</i></p>

Tuesday, September 23, 2008

7:00 – 4:00pm	<b>Registration</b> <i>Crystal Ballroom Foyer</i>
7:40 – 8:40am	<b>Corporate Sponsored Breakfast Sessions</b>
	<b>USP</b> <i>Old Georgetown</i> Developing Standards for Cell and Gene Therapy Products Biologics and Biotechnology at the United States Pharmacopeia (USP). <i>Breakfast available in the Old Georgetown Foyer</i>
	<b>Invitrogen</b> <i>Cabinet/Judiciary</i> Preparing for commercialization: Case studies in productivity enhancement and risk mitigation for cell therapy manufacturing. <i>Breakfast available in the Cabinet/Judiciary Foyer</i>
8:55 – 9:00am	<b>Introduction</b> <i>Crystal Ballroom</i>
9:00 – 10:30am	<b>Novel Therapies &amp; Enabling Technologies</b> <i>Crystal Ballroom</i> <b>Chair: Shelly Heimfeld, PhD</b> Director, Cellular Therapy Laboratory & cGMP Cell Processing Facility, Fred Hutchinson Cancer Research Center
	<b>Iron Labeling of CD133+ Cells</b> <b>Joseph A. Frank, MD</b> Chief, Laboratory of Diagnostic Radiology Research, Clinical Center, NIH
	<b>Adipose-Derived Stem Cells for Peripheral Vascular Disease</b> <b>Keith L. March, MD, PhD</b> Director, Indiana Center for Vascular Biology & Medicine, Indiana University
	<b>Cell Sorting for Cellular Therapeutics</b> <b>Andrew Balber, PhD</b> Chief Scientific Officer, Aldagen
10:30 - 11:00am	<b>Break &amp; Exhibits</b> <i>Crystal Ballroom Foyer</i>
11:00 – 12:30pm	<b>Novel Therapies</b> <i>Crystal Ballroom</i> <b>Chair: David McKenna Jr., MD</b> Medical Director, Clinical Cell Therapy Lab, University of Minnesota Medical Center
	<b>Non-Homologous Use of Cord Blood</b> <b>Mary J. Laughlin, MD</b> Associate Professor of Medicine and Pathology, Case Western Reserve University, Cleveland Cord Blood Center
	<b>Development of Muscle Cell Therapy for Incontinence</b> <b>Ron Jankowski, PhD</b> Director, Research & Product Development, Cook MyoSite, Inc.
	<b>Retinal Progenitor Cells</b> <b>Jonathan Dinsmore, PhD</b> Senior Vice President and General Manager, Advanced Cell Technology & Mytogen, Inc.

Tuesday, September 23, 2008 (continued)

12:40 – 2:00pm	<b>Lunch &amp; Presentations</b> <b>Update from the ISCT Legal &amp; Regulatory Committee</b> Kurt Gunter, MD Hospira, Inc. <b>CT Laboratories – How to get the Reimbursement You Deserve</b> John McMannis, PhD Director, Cell Processing Laboratory, MD Anderson Cancer Center Lunch available in the Crystal Ballroom Foyer
2:00 – 3:30pm	<b>Challenges for Manufacturing, Shipping, and On-site Preparation of CT Products</b> Crystal Ballroom <b>Chair: Carolyn Keever-Taylor, PhD</b> Director, BMT Processing Laboratories, Medical College of Wisconsin <b>Panel Presentations &amp; Discussion:</b> David McKenna Jr., MD University of Minnesota Medical Center <b>Robert Preti, PhD</b> President & CSO, Progenitor Cell Therapy, LLC <b>Jerrod Denham</b> Senior Manager, Manufacturing Sciences, Geron Corporation <b>Brian Flynn</b> Quality Manager, Genzyme Biosurgery
3:30 – 4:00pm	<b>Break &amp; Exhibits</b> Crystal Ballroom Foyer
4:00 – 5:30pm	<b>US Government Funding of Cellular Therapies</b> Crystal Ballroom <b>Chair: Liana Harvath, PhD</b> NHLBI, NIH <b>Panel Presentations &amp; Discussion:</b> Traci Mondoro, PhD NHLBI, NIH Lili Portilla, MPA National Center for Research Resources, NIH Mrunal Chapekar, PhD National Institute of Standards and Technology <b>Robert Baitty</b> Health Resources and Services Administration <b>David Badman, PhD</b> RAID Program, NIH

Wednesday, September 24, 2008

7:00 – 12:00pm	<b>Registration</b> Crystal Ballroom Foyer
7:15 – 8:15 am	<b>Breakfast</b> Crystal Ballroom Foyer
8:20 – 8:30am	<b>Introduction</b> Crystal Ballroom

Wednesday, September 24, 2008 (continued)

8:30 – 10:00am	<b>Manufacturing Challenges: Operational Issues &amp; Reports to the FDA</b> <i>Crystal Ballroom</i> Panel Chairs: Lynn O'Donnell, PhD // Janice Davis-Sproul, MAS <b>Panel Presentations &amp; Discussion:</b> <b>Thomas Finn, PhD</b> OCTGT, CBER, FDA <b>Katie Faria</b> Director, Process Development, Organogenesis Inc. <b>Gary du Moulin, PhD, MPH, RAC</b> Senior Director, Quality Compliance, Genzyme Biosurgery
10:00 – 10:30am	<b>Break</b> <i>Crystal Ballroom Foyer</i>
10:30 – 12:00pm	<b>Product Nomenclature</b> <i>Crystal Ballroom</i> Chair: John McMannis, PhD Director, Cell Processing Laboratory, MD Anderson Cancer Center <b>Kimberly Benton, PhD</b> Deputy Director, Division of Cellular & Gene Therapies, OCTGT, CBER, FDA <b>Lilia Bi</b> OCTGT, CBER, FDA <b>Darin Weber, PhD</b> Senior Consultant, Biologics Consulting Group, Inc <b>Fran Rabe</b> , Manager of Quality Assurance, University of Minnesota

**CO-CHAIRS:**

**Elizabeth J Read MD**, University of California, San Francisco  
**Janice Davis-Sproul MAS, MT(ASCP)** Johns Hopkins Medicine

**ORGANIZING COMMITTEE MEMBERS:**

**Kimberly Benton, PhD** OCTGT, CBER, FDA  
**Lee Buckler, BEd, LLB**, Progenitor Cell Therapy, LLC  
**Liana Harvath, PhD**, NHLBI, NIH  
**Shelly Heimfeld, PhD**, Fred Hutchinson Cancer Research Center  
**Carolyn Keever-Taylor, PhD**, Medical College of Wisconsin  
**Mary Laughlin, MD**, Case Western Reserve University  
**Bruce Levine, PhD**, University of Pennsylvania  
**John McMannis, PhD**, MD Anderson Cancer Center  
**David McKenna, MD**, University of Minnesota Medical Center  
**Lynn O'Donnell, PhD**, Ohio State University